{"id":"NCT00981409","sponsor":"GlaxoSmithKline","briefTitle":"The Treatment of Acute Pulmonary Thromboembolism (PE) of GSK576428 (Fondaparinux Sodium) in Japanese Patients","officialTitle":"Clinical Evaluation of GSK576428 (Fondaparinux Sodium) in the Treatment of Acute Pulmonary Thromboembolism (PE)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-07","primaryCompletion":"2008-12","completion":"2008-12","firstPosted":"2009-09-22","resultsPosted":"2009-12-10","lastUpdate":"2016-12-16"},"enrollment":41,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Embolism, Pulmonary"],"interventions":[{"type":"DRUG","name":"Fondaparinux sodium","otherNames":["GSK576428"]},{"type":"DRUG","name":"unfractionated heparin (UFH)","otherNames":[]}],"arms":[{"label":"Fondaparinux","type":"EXPERIMENTAL"},{"label":"unfractionated heparin","type":"OTHER"}],"summary":"The primary objective is to evaluate the efficacy (as measured by the rate of recurrent symptomatic Venous Thromboembolism \\[VTE\\] (i.e., Pulmonary thromboembolism \\[PE\\] and Deep Vein Thrombosis \\[DVT\\])) and safety of GSK576428 as the initial treatment in subjects with acute PE in an open-label design.","primaryOutcome":{"measure":"The Percentage of Participants With Recurrent or New Symptomatic Venous Thromboembolism (VTE)","timeFrame":"From Day 1 to Day 90 (Â±7 days)","effectByArm":[{"arm":"Fondaparinux Sodium (FPX)","deltaMin":0,"sd":null},{"arm":"Unfractionated Heparin (UFH)","deltaMin":0,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":25},"locations":{"siteCount":27,"countries":["Japan"]},"refs":{"pmids":["21512258"],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":31},"commonTop":["Haemorrhage subcutaneous","Constipation","Urinary tract infection","Back pain","Alanine aminotransferase increased"]}}